The present invention features compositions and methods for enhancing an anti-tumor response by administering an OX40 agonist (e.g., an anti-OX40 antibody) and/or an anti-CTLA4 antibody (e.g., a CTLA4-blocking antibody) in combination with a cancer therapy.